Ameriprise
RCUS icon

Ameriprise’s Arcus Biosciences RCUS Stock Holding History

Ameriprise’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Sell
153,813
-6,269
-4% -$155K ﹤0.01% 2587
2026
Q1 		$3.46M Sell
160,082
-65,831
-29% -$1.42M ﹤0.01% 2672
2025
Q4 		$5.38M Buy
225,913
+16,056
+8% +$328K ﹤0.01% 2378
2025
Q3 		$2.85M Buy
209,857
+54,362
+35% +$565K ﹤0.01% 2791
2025
Q2 		$1.27M Sell
155,495
-5,043
-3% -$43.1K ﹤0.01% 3170
2025
Q1 		$1.26M Sell
160,538
-1,387,053
-90% -$16.1M ﹤0.01% 3112
2024
Q4 		$23M Buy
1,547,591
+228,325
+17% +$3.73M 0.01% 1240
2024
Q3 		$20.2M Sell
1,319,266
-155,172
-11% -$2.45M 0.01% 1329
2024
Q2 		$22.5M Buy
1,474,438
+273,417
+23% +$4.41M 0.01% 1204
2024
Q1 		$22.7M Sell
1,201,021
-433,784
-27% -$7.5M 0.01% 1230
2023
Q4 		$31.2M Buy
1,634,805
+54,881
+3% +$877K 0.01% 1006
2023
Q3 		$28.4M Buy
1,579,924
+101,928
+7% +$2.05M 0.01% 1017
2023
Q2 		$30M Buy
1,477,996
+1,282,961
+658% +$24.4M 0.01% 1022
2023
Q1 		$3.56M Sell
195,035
-9,067
-4% -$173K ﹤0.01% 2543
2022
Q4 		$4.22M Sell
204,102
-4,956
-2% -$136K ﹤0.01% 2411
2022
Q3 		$5.47M Buy
209,058
+16,665
+9% +$441K ﹤0.01% 2151
2022
Q2 		$4.88M Buy
+192,393
New +$4.71M ﹤0.01% 2300
2021
Q4 		– Sell
-298,410
Closed -$10.4M – 4035
2021
Q3 		$10.4M Hold
298,410
– – ﹤0.01% 1823
2021
Q2 		$8.2M Sell
298,410
-1,071,985
-78% -$30.6M ﹤0.01% 2088
2021
Q1 		$38.5M Sell
1,370,395
-5,998
-0.4% -$209K 0.01% 896
2020
Q4 		$35.7M Buy
+1,376,393
New +$33.3M 0.01% 897

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ameriprise's RCUS Position: Q2 2026 in Review

Ameriprise reduced its Arcus Biosciences (RCUS) stake by 3.9% in Q2 2026, selling an estimated $155K and leaving 153,813 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Ameriprise first reported a position in RCUS in Q4 2020 and has held it in 21 quarters since. The position peaked at $38.5M in Q1 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Ameriprise held 153,813 shares of Arcus Biosciences worth $4.74M as of Q2 2026.
  • Ameriprise sold 6,269 Arcus Biosciences shares in Q2 2026, an estimated $155K.
  • Arcus Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2587 holding.
  • Ameriprise first reported a position in Arcus Biosciences in Q4 2020 and has held it in 21 quarters since.
  • Ameriprise's Arcus Biosciences position peaked at $38.5M in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.